40 results about "Heterotopic ossification" patented technology

The present invention relates to an exercise-assisting device, and more specifically to a seat able to move reciprocally automatically in the front-to-back direction, which is one of the constituent elements of a rowing machine constituting a remedial exercise device for physically disabled individuals, and particularly paraplegics, while also constituting a whole-body exercise device able to prevent heterotopic ossification.

Presented herein are systems and methods that facilitate automated segmentation of 3D images of subjects to distinguish between regions of heterotopic ossification (HO) normal skeleton, and soft tissue. In certain embodiments, the methods identify discrete, differentiable regions of a 3D image of subject (e.g., a CT or microCT image) that may then be either manually or automatically classified as either HO or normal skeleton.

The directional-ionizing energy emitting implant is for attachment either to natural tissue or a prosthetic device, and delivers a prescribed dosage of energy to targeted tissue. The insert device includes an energy-source material within the insert device that delivers the prescribed dosage of energy to the targeted tissue, while minimizing exposure of nontargeted tissue. The targeted tissue has a known energy-response profile and is adjacent to the targeted tissue. The energy-source material in combination with the prosthetic device defines an actual energy-delivery distribution field. The energy-delivery distribution field has a configuration similar to the known energy-responsive profile of the targeted tissue. The prescribed dosage of energy is applied from energy-source material within the insert device and directed to the targeted tissue. The prescribed energy dosage is determined by using known characteristics of the energy-source material, and by the placement of the energy-source material relative to the targeted tissue. The implant system reduces any occurrence of heterotopic ossification caused by the implant, inhibits growth or migration of benign or malignant living cells, and minimizes or even eliminates infectious processes or delayed keloid or scar formation induced from surgical placement of a functional prosthesis or fixation device, in tissue within or about the device due to its targeted therapeutic energy emission effects.

The invention relates to a cervical-vertebrajoint replacement device with vertebralpartial resection. The cervical-vertebrajoint replacement device with vertebralpartial resection comprises an upper hemivertebraprosthesis, a lower hemivertebraprosthesis and a cup-and-ball-jointintervertebral discprosthesis, wherein the lower surface of the upper hemivertebraprosthesis and the upper surface of thelower hemivertebraprosthesis are each provided with a clamping groove, the upper end and the lower end of the cup-and-ball-jointintervertebral discprosthesis are each provided with a buckle for beingin buckling cooperation with the clamping groove, and the upper surface of the upper hemivertebraprosthesis and the lower surface of the lower hemivertebraprosthesis are each provided with a fixing bolt. According to the cervical-vertebrajoint replacement device with vertebralpartial resection, three parts separated combinationprostheses are adopted, the space between the upper hemivertebraprosthesis and the lower hemivertebraprosthesis is adjustable, the cervical-vertebrajoint replacement device can be used for patients with obviously-narrow partial intervertebral space and patients withcompression factors located behind the vertebral body, and the indication range of a CDA operation is widened; a space structure is a 'metal to metal' space structure, an environmental basis formed by HO is eliminated accordingly, the side effect formed by an inhibition bone of NSAIDs does not need to be considered, HO prevention can be trustingly carried out with the NSAIDs, and the occurrence rate ofheterotopic ossification is decreased.

The invention discloses an application of microRNA-29b in articular cartilage repair as a drug target. According to the application disclosed by the invention, the research indicates that microRNA-29b is a key miRNA for regulating the hypertrophy change of MSCs after chondrogenic differentiation, therefore, the hypertrophy of MSCs-derived cartilage cells is inhibited by virtue of an microRNA-29b inhibitor, the phenotypes of the MSCs-derived cartilage cells are stabilized, and the fibrosis and the heterotopic ossification of tissue engineering cartilages are prevented, thus further realizing tissue engineering cartilage repair, and providing a new thought for tissue engineering cartilage construction, cartilage framework material design and cartilage repair.

The present disclosure relates to an artificial ankle joint talus component and, more particularly, to an artificial ankle joint talus component including a joint surface in contact with an insert and a contact surface in contact with a bone, wherein the contact surface may be formed to be complementary to a resected surface of a talus so as to cover the entire resected surface, thereby dispersing stress, and reducing after-effects of surgery, such as osteolysis, heterotopic ossification, or the like.

The present invention relates to novel mutants of bone morphogenetic proteins (BMPs) useful as inhibitors of heterotopic ossification. Specifically, the present invention relates to novel mutants containing only the entire region involved in the formation of finger 2 including the wrist epitope of a BMP with a specific cysteine residue or specific cysteine residues replaced by a different amino acid. The present invention also relates pharmaceutical compositions containing these mutants and to the use of the mutants and pharmaceutical compositions in therapy.

Presented herein are systems and methods that facilitate automated segmentation of 3D images of subjects to distinguish between regions of heterotopic ossification (HO) normal skeleton, and soft tissue. In certain embodiments, the methods identify discrete, differentiable regions of a 3D image of subject (e.g., a CT or microCT image) that may then be either manually or automatically classified as either HO or normal skeleton.

The present invention is directed to compositions and methods for the prevention or treatment of treatment of heterotopic ossification, vascular calcification, or pathologic calcification.

The invention provides a method of treating heterotopic ossification in a subject in need thereof. The method comprises administering a hypoxia inducible factor-1α (Hif-1α) inhibitor to the subject. In various embodiments, the Hif-1α inhibitor is PX-478, rapamycin, or digoxin.

The invention discloses a corrosion-resistant silk fibroin / hydroxyapatite / magnesia composite osteoinductive gel sponge and a preparation method thereof. The present invention uses soluble silk fibroin as a stabilizer to prepare nano-suspension with highly dispersed hydroxyapatite and osteoinductive magnesium oxide, and then embeds insoluble silk fibroin fibers to form a three-dimensional network gel, and uses freeze-drying technology to prepare silk Egg white / hydroxyapatite / magnesia gel sponge. After implantation in the gel sponge, it can absorb body fluid and shape it to stay in the injured part, and can maintain the gel state for a long time without being dissolved and lost; under the action of body fluid, the magnesium oxide in the gel sponge slowly degrades to produce magnesium ions and Generate local alkaline microenvironment, promote osteogenic differentiation of bone marrow mesenchymal stem cells, and have osteoinductive effect; the gel sponge can be directly filled in bone defects clinically, without inflammatory reaction and heterotopic ossification; the gel sponge The preparation method is simple.

The invention discloses an application of microRNA-29b in articular cartilage repair as a drug target. According to the application disclosed by the invention, the research indicates that microRNA-29b is a key miRNA for regulating the hypertrophy change of MSCs after chondrogenic differentiation, therefore, the hypertrophy of MSCs-derived cartilage cells is inhibited by virtue of an microRNA-29b inhibitor, the phenotypes of the MSCs-derived cartilage cells are stabilized, and the fibrosis and the heterotopic ossification of tissue engineering cartilages are prevented, thus further realizing tissue engineering cartilage repair, and providing a new thought for tissue engineering cartilage construction, cartilage framework material design and cartilage repair.